Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Treatment
Researchers from Italy, Germany and the the Netherlands report details of new studies and findings in the area of cancer treatment
May 10th, 2006
Cancer treatment data are the focus of recent research from Italy, Germany and the the Netherlands. Study 1: Anaplastic lymphoma kinase is a lymphoma antigen suitable for immune interventions. According to a study from Italy, "Anaplastic lymphoma kinase (ALK) oncogenic fusion proteins, expressed in about 60% of anaplastic large cell lymphomas (ALCL), are tumor-specific molecular targets for such a malignancy. One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate whether ALK is a tumor-associated antigen suitable for immune interventions. The frequency and the functional phenotype of the anti-ALK...
Source: Vaccine Weekly (2006-05-10)
|
